B. I. Bae, H. Xu, S. Igarashi, M. Fujimuro, N. Agrawal et al., p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease, vol.47, pp.29-41, 2005.

K. Bantubungi, C. Jacquard, A. Greco, A. Pintor, A. Chtarto et al., Minocycline in phenotypic models of Huntington's disease, Neurobiol. Dis, vol.18, pp.206-217, 2005.

M. F. Beal, Energetics in the pathogenesis of neurodegenerative diseases, vol.23, pp.298-304, 2000.

A. Benchoua, Y. Trioulier, D. Zala, M. C. Gaillard, N. Lefort et al., Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin, Mol. Biol. Cell, vol.17, pp.1652-1663, 2006.

N. Bizat, J. Hermel, F. Boyer, C. Jacquard, C. Creminon et al., Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease, J. Neurosci, vol.23, pp.5020-5030, 2003.

E. Brouillet, F. Conde, M. F. Beal, and P. Hantraye, Replicating Huntington's disease phenotype in experimental animals, Prog. Neurobiol, vol.59, pp.427-468, 1999.

E. Brouillet, C. Jacquard, N. Bizat, and D. Blum, 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease, J. Neurochem, vol.95, pp.1521-1540, 2005.

C. Carrascosa, I. Torres-aleman, C. Lopez-lopez, E. Carro, L. Espejo et al., Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration, Biomaterials, vol.25, pp.707-714, 2004.

E. Carro, J. L. Trejo, S. Busiguina, and I. Torres-aleman, Circulating insulinlike growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy, J. Neurosci, vol.21, pp.5678-5684, 2001.

E. Carro, J. L. Trejo, T. Gomez-isla, D. Leroith, and I. Torres-aleman, Serum insulin-like growth factor I regulates brain amyloid-beta levels, Nat. Med, vol.8, pp.1390-1397, 2002.

E. Carro, J. L. Trejo, A. Nunez, and I. Torres-aleman, Brain repair and neuroprotection by serum insulin-like growth factor I, Mol. Neurobiol, vol.27, pp.153-162, 2003.

C. Escartin, F. Boyer, A. P. Bemelmans, P. Hantraye, and E. Brouillet, Insulin growth factor-1 protects against excitotoxicity in the rat striatum, Neuroreport, vol.15, pp.2251-2254, 2004.
URL : https://hal.archives-ouvertes.fr/cea-02290615

L. A. Farrer, Diabetes mellitus in Huntington disease, Clin. Genet, vol.27, pp.62-67, 1985.

J. G. Greene and J. T. Greenamyre, Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate, J. Neurochem, vol.64, pp.430-436, 1995.

R. E. Humbel, Insulin-like growth factors I and II, Eur. J. Biochem, vol.190, pp.445-462, 1990.

S. Humbert, E. A. Bryson, F. P. Cordelieres, N. C. Connors, S. R. Datta et al., The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt, Dev. Cell, vol.2, pp.831-837, 2002.

S. Humbert and F. Saudou, Neuronal death in Huntington's disease: multiple pathways for one issue, Neuronal Death by Accident or by Design, pp.137-152, 2001.

M. S. Hurlbert, W. Zhou, C. Wasmeier, F. G. Kaddis, J. C. Hutton et al., Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes Diabetes, vol.48, pp.649-651, 1999.

C. Jacquard, Y. Trioulier, F. Cosker, C. Escartin, N. Bizat et al., Brain mitochondrial defects amplify intracellular [Ca 2+ ] rise and neurodegeneration but not Ca 2+ entry during NMDA receptor activation, FASEB J, vol.20, pp.1021-1023, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00103460

B. K. Kaspar, J. Llado, N. Sherkat, J. D. Rothstein, and F. H. Gage, Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model, Science, vol.301, pp.839-842, 2003.

X. F. Liu, J. R. Fawcett, R. G. Thorne, T. A. Defor, and W. H. Frey-2nd, Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage, J. Neurol. Sci, vol.187, pp.91-97, 2001.

R. T. Matthews, L. Yang, B. G. Jenkins, R. J. Ferrante, B. R. Rosen et al., Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease, J. Neurosci, vol.18, pp.156-163, 1998.

V. Mittoux, S. Ouary, C. Monville, F. Lisovoski, T. Poyot et al., Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration, J. Neurosci, vol.22, pp.4478-4486, 2002.
URL : https://hal.archives-ouvertes.fr/cea-02290628

S. Palfi, D. Riche, E. Brouillet, M. C. Guyot, V. Mary et al., Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration, Exp. Neurol, vol.146, pp.135-141, 1997.

A. V. Panov, C. A. Gutekunst, B. R. Leavitt, M. R. Hayden, J. R. Burke et al., Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines, Nat. Neurosci, vol.5, pp.731-736, 2002.

H. J. Schneider, U. Pagotto, and G. K. Stalla, Central effects of the somatotropic system, Eur. J. Endocrinol, vol.149, pp.377-392, 2003.

, The Huntington study group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, vol.72, pp.971-983, 1993.

F. O. Walker and L. A. Raymond, Targeting energy metabolism in Huntington's disease, Lancet, vol.364, pp.312-313, 2004.

J. Woelfle, D. J. Chia, M. B. Massart-schlesinger, P. Moyano, and P. Rotwein, Molecular physiology, pathology, and regulation of the growth hormone/insulin-like growth factor-I system, Pediatr. Nephrol, vol.20, pp.295-302, 2005.